CONNECT WITH US
HealthTech

HealthTech

Combining targeted therapies significantly boosted survival in kidney cancer study

Medical Xpress logo

Published on

Add as a preferred source on Google
Combining targeted therapies significantly boosted survival in kidney cancer study

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Results of a phase 1/2 trial led by Roswell Park Comprehensive Cancer Center show that combining the targeted therapies bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progression-free and overall survival in patients with the most common type of kidney cancer. Saby George, M.D., FACP, professor of oncology in the Department of Medicine, is principal investigator of the trial and first author of the study, newly published in The Lancet Oncology.

The strongest benefit was seen in favorable-risk patients, who made up the majority of the 51 patients enrolled in the nationwide clinical trial, NCT01684397, conducted at five academic cancer centers.

"This novel regimen of pazopanib alternating with bevacizumab was found to be safe and efficacious in untreated patients with advanced clear cell kidney cancer," says George. "The regimen was also reasonably well tolerated by patients and delayed development of treatment resistance leading to prolonged progression-free survival."

3 months. 7 months.



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.